Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Cara Therapeutics Inc. (NASDAQ: CARA) shares increased 2.90 percent to close at $14.90 a share Tuesday. The stock traded between $14.70 and $15.75 on volume 474,413 shares traded. Analysts at Canaccord have recently initiated coverage on the company with a “buy” rating and a price target of $25.00. Shares of Cara Therapeutics have gained approximately 15.0 percent year-to-date.
Find out more about Cara Therapeutics including full access to the free equity report at:
Kindred Biosciences Inc. (NASDAQ: KIN) increased 12.75 percent to close at $24.94 a share Tuesday. The stock traded between $23.00 and $25.75 on volume of 326,272 shares traded. Analysts at BMO Capital have recently upgraded the company’s rating to “outperform” from “market perform”. Shares of Kindred Biosciences have gained approximately 100.0 percent year-to-date.
Find out more about Kindred Biosciences including full access to the free equity report at:
Orion Energy Systems, Inc. (NYSEMKT: OESX) shares increased 12.95 percent to close at $5.67 a share Tuesday. The stock traded between $5.50 and $6.05 on volume of 763,517 shares traded. Analysts at Craig-Hallum have recently initiated coverage on the company with a “buy” rating and a price target of $9.00. Shares of Orion Energy Systems have fallen approximately 16.0 percent year-to-date.
Find out more about Orion Energy Systems including full access to the free equity report at:
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares gained 1.71 percent to close at $59.00 a share Tuesday. The stock traded between $58.00 and $63.85 on volume of 244,399 shares traded. Analysts at JPMorgan have recently initiated coverage on the company with an “overweight” rating and a price target of $66.00. Shares of Ultragenyx have gained approximately 40.0 percent year-to-date.
Find out more about Ultragenyx Pharmaceutical including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing